First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients

Inclusion Criteria: * Signed informed consent (i.e. date of study entry (T0)) * Age ≥ 18 years at the time of signing informed consent * Diagnosis with a histologically or cytologically confirmed solid tumor of the pancreas, esophagus, liver or ovaries that is advanced, recurrent or progressing after at least first-line anti-cancer treatment, or for which no alternative standard therapy is available due to intolerance to or refusal of standard-of-care treatment. * Adequate hematological blood values following previous anti-cancer treatments, as judged by the Principal Investigator * All treatment-related toxicities must have resolved to CTCAE grade ≤ 2 or must be stable and well controlled with minimal, local or non-invasive intervention, as judged by the Principal Investigator * Reasonable life expectancy of at least 3 months, as estimated by the Principal Investigator * At least 1 measurable or evaluable lesion as defined by the latest version of Immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) guidelines * Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained at the time of screening: * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1500/µL) without granulocyte colony-stimulating factor support * Lymphocyte count ≥ 0.5 x 109/L (500/µL) * Platelet count ≥ 100 x 109/L (100,000/µL) without transfusion * Hemoglobin ≥ 90 g/L (9 g/dL) (Patients may be transfused to meet this criterion) * Aspartate…